Aurobindo Pharma Subsidiary Launches Adquey Ointment in US Dermatology Market
Aurobindo Pharma's subsidiary Acrotech Biopharma has launched Adquey ointment in the US, marking its entry into the American dermatology market. Adquey, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in patients aged two and above, was discovered by Otsuka Pharmaceutical and licensed to Acrotech for US commercialization. The product will compete in a market estimated at around $1.3 billion by July 2026. Acrotech has established a dedicated dermatology unit to support this launch and expand its presence.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 37/100.
Outlets measured: businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 30 Sept, 05:16 pm. Other outlets followed.
- 1